Pancreas Graft Outcome by Immunosuppression Therapy

• Pancreas graft function with or without anti-T-cell agents was analyzed by recipient category.

• For initial maintenance immunosuppression, regimens (induction therapy), outcome was analyzed for the 4 most common combinations, all of which included cyclosporine (CsA), Azathioprin (Aza), tacrolimus (Tac) [FK506], Mycophenalate Mofetil (MMF).

• The majority of the pancreas transplant recipients received one or both of the new immunosuppression drugs of this era: Tac and MMF.

Pancreas Graft Function by Anti-T Cell Induction (USA)

About three-fourths of US cadaveric SPK 1994-1998 recipients received monoclonal (ATG) or polyclonal (OKT3) anti-T-cell agents for induction therapy. The pancreas graft survival rate was not significantly different with or without anti-T-cell agents at one year: 81-84% (Figure 16).

Figure 16

For 1994-1998 US cadaveric PAK cases, pancreas graft survival was significantly higher with anti-T-cell agents compared to without them: at one year, ATG = 77%; OKT3 = 67%; None = 61% (Figure 17).

Figure 17

For 1994-1998 US cadaveric PTA cases, there was not a significant difference in pancreas graft survival (p=>0.18) with the use of anti-T-cell agents (Figure 18).

Figure 18